South China Morning Post·4 min read·medium
Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial
D
Dannie Peng
✦AI Summary
The death of a six-year-old girl in a gene-editing trial has sparked concerns about the future of China's flexible clinical research regulations. Industry experts fear that this tragedy may lead to a regulatory crackdown, potentially slowing down China's rapid advancements in biotechnology.
The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards.
sciencehealthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in